Home Knightsbridge Insights Commentary: Paul Ebeling on Wall Street, Special Report on the Omicron Hype

Commentary: Paul Ebeling on Wall Street, Special Report on the Omicron Hype

by Paul Ebeling

#PaulEbeling #WallStreet #bullish #finantial #markets #stocks #inflation #Biden #Trump #virus

$DIA $SPY $QQQ $RUT $VXX

“Stock futures jumped Monday morning to recover from Friday’s technical test as expected” — Paul Ebeling

Friday’s 2%+ market decline was assumed to be on incoming information on the Omicron variant it was not, it was a technical test and none of the benchmarks up trends were effected, but…

…the current state of play in this hyped VirusCasedemic news cycle is this:

  • Moderna thinks it may be able to develop a new vaccine to fight the Omicron variant by early 2022. “If we have to make a brand new vaccine I think that’s going to be early 2022 before that’s really going to be available in large quantities,” said Paul Burton, Moderna’s chief medical officer, in a Sunday BBC interview. Moderna stock was up 20% on Friday. Hot take: I think this commentary may alleviate a little of the angst among medium to longer-term investors, with the emphasis on a little.
  • Dr. Anthony Fauci told “Face the Nation” on Sunday the U.S. “has the potential to go into a fifth wave” of the pandemic. Hot take: Obviously worrisome, and will only fuel the near-term bearish narrative. 
  • Travel restrictions are on the rise from developed economies as officials run their COVID-19 protection playbooks. CNN has a solid breakdown of where the travel bans have kicked in. Hot take: Here comes talk of lockdowns. “If border restrictions are not effective and variant characteristics are as bad as some fear, there is risk more lockdowns will be needed to avoid overrunning health systems, at the very least in affected regions. Some health departments may lean towards taking early precautionary action to avoid much greater economic risks down the track,” points out JPMorgan’s research team.
  • On Sunday, Germany and Italy confirmed their first Omicron cases. Hot take: Those reports will feed the short-term bear take that COVID mutations are spreading quickly and are resistant to current vaccines.

The Bull thesis on stocks is in place.

The S&P 500 entered these latest virus fearmongering hype trading on a P/E ratio of just 2 pts higher than 2yrs ago.

Supply chain problems are going to be with corporate America into Y 2022, and a Key risk to Q-4 earnings for liquor makers Diageo and Brown-Forman is the ongoing bottle shortage.

Looking Ahead: There is a NFPs jobs report on Friday.

Have a healthy, prosperous week, Keep the Faith!

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.
CLOSE